Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation

Biotech Giants' SG&A Expenses: A Decade of Strategic Growth

__timestampAscendis Pharma A/SDynavax Technologies Corporation
Wednesday, January 1, 2014627400017763000
Thursday, January 1, 2015941500022180000
Friday, January 1, 20161150400037257000
Sunday, January 1, 20171348200027367000
Monday, January 1, 20182505700064770000
Tuesday, January 1, 20194847300074986000
Wednesday, January 1, 20207666900079256000
Friday, January 1, 2021160180000100156000
Saturday, January 1, 2022221227000131408000
Sunday, January 1, 2023264410000152946000
Monday, January 1, 2024284545000
Loading chart...

In pursuit of knowledge

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing costs is crucial for success. Ascendis Pharma A/S and Dynavax Technologies Corporation, two prominent players, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Ascendis Pharma A/S has seen a staggering increase of over 4,100% in SG&A expenses, reflecting its aggressive expansion and investment in growth. In contrast, Dynavax Technologies Corporation's expenses have grown by approximately 760%, indicating a more measured approach.

Key Insights

  • 2014-2018: Both companies maintained relatively modest SG&A expenses, with Ascendis Pharma A/S starting at $6.3 million and Dynavax at $17.8 million.
  • 2019-2023: Ascendis Pharma A/S's expenses surged, reaching $264 million by 2023, while Dynavax's expenses grew to $153 million.

These trends highlight the strategic differences in cost management and growth trajectories between the two companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025